https://www.selleckchem.com/products/amg-232.html
39 (p = 0.89) and the GV-971 900-mg group (n = 83) was - 2.58 (p = 0.3. The treatment responders according to CIBIC-Plus assessment were significantly higher in the GV-971 900-mg group than the placebo group (92.77% vs. 79.52%, p 0.05). The GV-971 900-mg subgroup showed a lower decline of cerebral metabolic rate for glucose than the placebo subgroup at the left precuneus, right posterior cingulate, bilateral hippocampus, and bilateral inferior orbital frontal at uncorrected p = 0.05. The respective rates of treatment-related AEs
Like
Comment
Share
